Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAzaro Pedrazzoli, Analía Beatriz
dc.contributor.authorDe Vos, Filip
dc.contributor.authorSepúlveda, Juan Manuel
dc.contributor.authorYung, W. K. Alfred
dc.contributor.authorWen, Patrick Y.
dc.contributor.authorvan den Bent, Martin
dc.date.accessioned2021-10-22T11:40:36Z
dc.date.available2021-10-22T11:40:36Z
dc.date.issued2020-01
dc.identifier.citationvan den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, et al. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol. 2020 Jan;146:79–89.
dc.identifier.issn1573-7373
dc.identifier.urihttps://hdl.handle.net/11351/6452
dc.descriptionBuparlisib; Capmatinib; Glioblastoma
dc.description.sponsorshipThis study is funded by Novartis Institutes for Biomedical Research (China). A.B. Lassman was supported in part by grants P30CA013696 and UG1CA189960 from the NCI.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesJournal of Neuro-Oncology;146
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectGlioblastoma multiforme
dc.subjectCervell - Càncer - Quimioteràpia
dc.subject.meshGlioblastoma
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshNeoplasm Recurrence, Local
dc.titleA Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s11060-019-03337-2
dc.subject.decsglioblastoma
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decsrecurrencia neoplásica local
dc.relation.publishversionhttps://doi.org/10.1007/s11060-019-03337-2
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[van den Bent M] Erasmus University Medical Center (MC) Cancer Institute, Rotterdam, The Netherlands. [Azaro A] Unitat d’Investigació de Teràpia Molecular, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [De Vos F] University Medical Center Utrecht, Utrecht, The Netherlands. [Sepulveda J] Hospital Universitario, 12 de Octubre, Madrid, Spain. [Yung WKA] MD Anderson Cancer Center, Houston, TX, USA. [Wen PY] Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
dc.identifier.pmid31776899
dc.identifier.wos000500801900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple